Jill Wechsler
Jill Wechsler
Washington editor
Washington Report
jwechsler@advanstar.com
Jill Wechsler is a veteran Washington reporter specializing in government policies that affect biomedical research and development and health care delivery in the US and abroad. She regularly writes about the Food and Drug Administration, Congress and federal and state policies as Washington editor of Pharmaceutical Executive, Pharmaceutical Technology, Applied Clinical Trials, BioPharm International and Managed Healthcare Executive magazines - all published by Advanstar Communications. In her career as a writer and editor she has contributed to a number of national consumer and specialized publications including Money Magazine, The Washington Post, Working Woman, American Artist, Dun's Review, and Good Housekeeping.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
